XML 85 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Borrowings - Silver Creek Convertible Notes - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2016
May 31, 2016
Dec. 31, 2012
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Sep. 05, 2017
Jun. 30, 2017
Mar. 31, 2017
Aug. 31, 2016
Debt Instrument [Line Items]                          
Preferred stock issued 0       0 0       0      
Proceeds from sale of preferred stock         $ 3,994,000 $ 3,361,000 $ 2,083,000            
Silver Creek Pharmaceuticals Inc [Member] | Convertible Notes [Member]                          
Debt Instrument [Line Items]                          
Interest rate (as a percent)   6.00%                      
Aggregate principal amount   $ 1,000,000                     $ 200,000
Debt instrument conversion price per share   $ 1.60                      
Minimum gross proceeds for next equity financing conversion   $ 4,000,000                      
Silver Creek Pharmaceuticals Inc [Member] | Series B Preferred Stock [Member] | Convertible Notes [Member]                          
Debt Instrument [Line Items]                          
Debt instrument conversion price per share $ 1.35         $ 1.35              
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member]                          
Debt Instrument [Line Items]                          
Preferred stock issued       2,000,000                  
Preferred stock price per share       $ 1.50                  
Warrants to purchase 1,900,000     1,700,000 1,900,000 1,900,000         300,000 1,800,000  
Proceeds from sale of preferred stock       $ 2,900,000                  
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | Milestone Event 1 [Member]                          
Debt Instrument [Line Items]                          
Description of milestone event achievement         Milestone Event 1 is defined as the date that is seven business days following the acceptance by the FDA of Silver Creek’s filing of an investigational new drug application (“IND”), or 30 business days after the IND is filed without FDA rejection of the application.                
Number of warrants exercisable         1,200,000                
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | Milestone Event 2 [Member]                          
Debt Instrument [Line Items]                          
Description of milestone event achievement         Milestone Event 2 is defined as the date that is seven business days following the date when Silver Creek completes a Phase 1 clinical trial, provided that if Silver Creek receives proceeds of less than $4.0 million pursuant to the sale of Series C preferred stock, Milestone Event 2 means the date that is seven business days following the first dose in humans in a clinical trial                
Number of warrants exercisable         700,000                
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | Prior to the Achievement of Milestone Event 1 [Member]                          
Debt Instrument [Line Items]                          
Warrants exercise price per share         $ 1.75                
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | On or After the Achievement of Milestone Event 1 [Member]                          
Debt Instrument [Line Items]                          
Warrants exercise price per share         2.25                
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | Prior to the Achievement of Milestone Event 2 [Member]                          
Debt Instrument [Line Items]                          
Warrants exercise price per share         2.25                
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | On or After the Achievement of Milestone Event 2 [Member]                          
Debt Instrument [Line Items]                          
Warrants exercise price per share         $ 2.75                
Silver Creek Pharmaceuticals Inc [Member] | Silver Creek Series C Preferred Stock [Member] | Convertible Notes [Member]                          
Debt Instrument [Line Items]                          
Debt instrument conversion price per share $ 1.50         $ 1.50              
Preferred stock issued 1,500,000         1,500,000              
Preferred stock price per share $ 1.50         $ 1.50              
Debt conversion, shares issued 800,000                        
Silver Creek Pharmaceuticals Inc [Member] | Maximum [Member] | Silver Creek Series C Preferred Stock [Member] | Milestone Event 2 [Member]                          
Debt Instrument [Line Items]                          
Proceeds from sale of preferred stock         $ 4,000,000                
Silver Creek Convertible Note [Member] | Silver Creek Pharmaceuticals Inc [Member]                          
Debt Instrument [Line Items]                          
Gross proceeds from the debt issuance     $ 1,600,000         $ 1,000,000 $ 900,000        
Interest rate (as a percent)         6.00%                
Discount on automatic conversion into the next qualifying equity financing (as a percent)     25.00%                    
Derivative liability     $ 200,000                    
Silver Creek Convertible Note [Member] | Silver Creek Pharmaceuticals Inc [Member] | Minimum [Member]                          
Debt Instrument [Line Items]                          
Amount of gross proceeds from qualifying equity financing in which holders would automatically convert into the next qualifying equity financing at a 25% discount     $ 4,000,000